Idiopathic Pulmonary Fibrosis: Epidemiology Forecast to 2034

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$9995

Idiopathic pulmonary fibrosis (IPF), a type of interstitial lung disease (ILD), is a serious chronic condition that affects the tissue surrounding the air sacs, or alveoli, in the lungs (National Heart Lung and Blood Institute, 2023). Environmental factors such as smoking, chronic aspiration, or respiratory infections, combined with advancing age, are the likely driving factors for the pathogenesis of IPF by causing respiratory alveolar epithelial injury (Sankari, Chapman and Ullah, 2024). These factors can cause permanent scarring in the lungs, called fibrosis. Fibrosis can cause the lungs to become thick and stiff over time, which makes it progressively more difficult to breathe (National Heart Lung and Blood Institute, 2023). Classic features of IPF include the gradual onset of shortness of breath, known as progressive dyspnea, and a dry, nonproductive cough (National Heart Lung and Blood Institute, 2023; Sankari, Chapman and Ullah, 2024; Moreno Diaz, Caballeria and Sellar Torres, 2025). However, some patients may stay asymptomatic for a long time. The development of the disease involves a complex interplay of genetic and immunological factors (Moreno Diaz, Caballeria and Sellar Torres, 2025). The risk for IPF is higher in smokers or those with a family history of IPF (National Heart Lung and Blood Institute, 2023). Research studies indicate that IPF risk increases with advancing age, and the prevalence of IPF is higher in males compared to females (Raghu et al., 2006, 2014, 2016; Agabiti et al., 2014; Natsuizaka et al., 2014; Harari et al., 2016; Strongman, Kausar and Maher, 2018; Navaratnam and Hubbard, 2019; Kreuter et al., 2022; Fan et al., 2024; Gupta et al., 2024).
In the 7MM, diagnosed prevalent cases of IPF are expected to increase from 199,146 cases in 2024 to 230,591 cases in 2034, at an annual growth rate (AGR) of 1.58%. In 2034, the US will have the highest number of diagnosed prevalent cases of IPF in the 7MM, with 134,778 cases, whereas the UK will have the fewest diagnosed prevalent cases of IPF with 11,730 cases. GlobalData epidemiologists attribute the change in the diagnosed prevalent cases of IPF to changing prevalence trends in Germany, Italy, and the UK as well as the changes in population dynamics in each market over the forecast period.

Scope

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for IPF in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for diagnosed prevalent cases of IPF, segmented by sex and age (18 years and older) in these markets. This epidemiology forecast for IPF is supported by data obtained from peer-reviewed articles. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast diagnosed prevalent cases of IPF across these markets. The epidemiology model corresponding to this report additionally provides the diagnosed incident cases of IPF, segmented by sex and age (18 years and older).

Reasons to Buy

The Idiopathic pulmonary fibrosis (IPF) epidemiology series will allow you to –

Develop business strategies by understanding the trends shaping and driving the global IPF market.

Quantify patient populations in the global IPF market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups that present the best opportunities for IPF therapeutics in each of the markets covered.

Table of Contents

List of Contents

List of Tables

List of Figures

1 Idiopathic Pulmonary Fibrosis: Executive Summary

1.1 Catalyst

1.2 Related reports

1.3 Upcoming reports

2 Epidemiology

2.1 Disease background

2.2 Risk factors and comorbidities

2.3 Global and historical trends

2.4 7MM forecast methodology

2.4.1 Sources

2.4.2 Forecast assumptions and methods

2.4.3 Forecast assumptions and methods: diagnosed prevalent cases of IPF

2.5 Epidemiological forecast for IPF (2024–34)

2.5.1 Diagnosed prevalent cases of IPF

2.5.2 Age-specific diagnosed prevalent cases of IPF

2.5.3 Sex-specific diagnosed prevalent cases of IPF

2.6 Discussion

2.6.1 Epidemiological forecast insight

2.6.2 Limitations of the analysis

2.6.3 Strengths of the analysis

3 Appendix

3.1 Bibliography

3.2 About the authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Vice President of Disease Intelligence and Epidemiology

3.2.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Contact Us

Table

Table 1: Summary of updated data types

Table 2: Risk factors and comorbidities for IPF

Figures

Figure 1: 7MM, diagnosed prevalent cases of IPF, both sexes, N, ages ≥18 years, 2024 and 2034

Figure 2: 7MM, diagnosed prevalence of IPF (%), both sexes, ages ≥18 years, 2024

Figure 3: 7MM, sources used and not used to forecast the diagnosed prevalent cases of IPF

Figure 4: 7MM, diagnosed prevalent cases of IPF, N, both sexes, ages ≥18 years, 2024

Figure 5: 7MM, diagnosed prevalent cases of IPF by age, N, both sexes, 2024

Figure 6: 7MM, diagnosed prevalent cases of IPF by sex, N, ages ≥18 years, 2024

Idiopathic Pulmonary Fibrosis: Epidemiology Forecast to 2034 standard reports
Currency USD
$9,995

Can be used by individual purchaser only

$29,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Idiopathic Pulmonary Fibrosis: Epidemiology Forecast to 2034 in real time.

  • Access a live Idiopathic Pulmonary Fibrosis: Epidemiology Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.